HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome

Wooltorton, Eric
April 2002
CMAJ: Canadian Medical Association Journal;4/16/2002, Vol. 166 Issue 8, p1067
Academic Journal
Reports on the association between the HIV drug stavudine and symptoms mimicking Guillain-Barré syndrome (GBS) as reported by drug company Bristol-Myers Squibb in a warning letter to physicians. Details about stavudine, a thymidine analogue and nucleoside analogue reverse transcriptase inhibitor (NRTI); Symptoms associated with stavudine use, including lactic acid abnormalities from hyperlactatemia to potentially fatal lactic acidosis syndrome (LAS). INSET: Guillain-Barré syndrome.


Related Articles

  • Changing Morbidity of Cutaneous Diseases in Patients with HIV After the Introduction of Highly Active Antiretroviral Therapy Including a Protease Inhibitor. Calista, D.; Morri, M.; Stagno, A.; Boschini, A. // American Journal of Clinical Dermatology;2002, Vol. 3 Issue 1, p59 

    Background: Highly active antiretroviral therapy (HAART) is a combination of an HIV protease inhibitor (PI), one or two reverse transcriptase inhibitors (RTIs) and/or non-nuclease reverse transcriptase inhibitors (NNRTIs). This combination therapy is able to reduce peripheral HIV viral load,...

  • Update: Guillain-Barré Syndrome Among Recipients of Menactra Meningococcal Conjugate Vaccine -- United States, June 2005-September 2006. Woo, E. J.; Ball, R.; Braun, M.; Clark, T.; Messonnier, N. Rosenstein; Wharton, M.; Vellozzi, C.; Campbell, S.; Weintraub, E.; Davis, R. // MMWR: Morbidity & Mortality Weekly Report;10/20/2006, Vol. 55 Issue 41, p1120 

    The article presents an update on the possible association between Guillain-Barrae Syndrome (GBS) and receipt of meningococcal conjugate vaccine (MCV4). Eight confirmed cases of GBS within 6 weeks after MCV4 vaccination has been identified from March 2005 to February 2006. Nine additional GBS...

  • Ciclosporin.  // Reactions Weekly;3/18/2006, Issue 1093, p11 

    Discusses research being done on the adverse-drug reaction to ciclosporin. Reference to study being done by J. A. Falk et al., which appeared in the January 2006 issue of the "Journal of Heart and Lung Transplantation"; Overview of the medical condition of a patient who undergone lung...

  • Delavirdine. Tran, Jonathan Q.; Gerber, John G.; Kerr, Bradley M. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 3, p207 

    Provides information on a study which reviewed the clinical pharmacokinetics of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), a potent and specific inhibitor of HIV-1 reverse transcriptase. Pharmacokinetic properties; Pharmacodynamic properties; Drug interactions.

  • Substitution of a Nonnucleoside reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA. Raffi, Francois; Bonnet, Benedicte; Ferre, Virginie; Esnault, Jean-Luc; Perre, Philippe; Reliquet, Veronique; Leautez, Sophie; Bouillant, Christine; Vergnoux, Odile; Weinbreck, Pierre; Mayer, Kenneth H. // Clinical Infectious Diseases;11/1/2000, Vol. 31 Issue 5, p1274 

    Presents a study that investigated the efficacy and tolerance of substituting a nonnucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients whose plasma viral load was controlled by a PI regimen. Overall tolerance of NNRTI; Side effects experienced by...

  • Reverse Transcriptase Inhibitors. Tripp, Ernest // Access;Jul2001, Vol. 15 Issue 6, p42 

    Explores the use of reverse transcriptase inhibitors in the management of HIV infections. Two ways on how reverse transcriptase inhibitors target HIV; Common reverse transcriptase medications; Drug combinations used in treating HIV infections.

  • New option for first-line treatment of HIV. Lucas, Beverly D. // Patient Care;3/15/1999, Vol. 33 Issue 5, p12 

    Reveals that physicians have an option to prescribe non-nucleoside reverse transcriptase inhibitor efavirenz as a first-line therapy for treating HIV infection. Effectiveness of the drug compared with a protease inhibitor; Recommended treatment regimen using efavirenz; Administration of...

  • Ipilimumab.  // Reactions Weekly;5/14/2011, Issue 1351, p29 

    The article describes the case of a 57-year-old female patient with Guillain-Barre syndrome while she is undergoing ipilimumab treatment.

  • Glatiramer acetate.  // Reactions Weekly;6/14/2012, Issue 1410, p24 

    The article describes the case of a 43-year-old man with relapsing-remitting multiple sclerosis who developed Guillain-Barre syndrome after receiving glatiramer acetate.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics